SCHEMBL5879149

SCHEMBL5879149

COc1cccc2[nH]cc(C3=CC(=O)NC3=O)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.47
HTR2B P41595 2/20 0.46
HTR1A P08908 1/20 0.46
HTR7 P34969 1/20 0.46
HTR5A P47898 1/20 0.46
MMP9 P14780 1/20 0.44
HTR6 P50406 1/20 0.42
HTR2C P28335 1/20 0.42
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.40
KDR P35968 3/20 0.39
FLT3 P36888 2/20 0.39
GSK3B P49841 2/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
NUAK1 O60285 1/20 0.39
ABL1 P00519 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879204 0.83 KDR (0.36) HTR1AHTR7HTR6MTNR1AMTNR1B
SCHEMBL10433668 0.83 KDR (0.40) HTR1AHTR7HTR6MTNR1AMTNR1B
SCHEMBL5879276 0.82 GPR84 (0.44) HTR2AGSK3BABL1CDK4CCND1
SCHEMBL5879293 0.79 HTR2B (0.43) HTR2AHTR2BHTR1AHTR7HTR5A
SCHEMBL5879188 0.79 FFAR1 (0.44) HTR2AHTR2BHTR1AHTR7HTR6
SCHEMBL5879162 0.79 CLK1 (0.45) HTR2BHTR1AHTR7HTR5AHTR6
SCHEMBL5879234 0.79 GPR84 (0.44) ABL1CDK4CCND1CDK2PRKCB
SCHEMBL5879280 0.79 CYP2A6 (0.45) ABL1CDK4CCND1CDK2PRKCB
SCHEMBL5879128 0.78 KDM4E (0.48) HTR2AHTR6MTNR1AMTNR1BKDR
SCHEMBL28504830 0.76 CDC25B (0.46) HTR2AHTR2BHTR1AHTR7HTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 HTR2A 1977/4885HTR2B 2815/4885HTR1A 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.